Pituitary ACTH Hypersecretion (Cushing Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Pituitary ACTH Hypersecretion Pipeline Drugs Market Report Overview
Cushing’s disease is a condition that results from hypersecretion of adrenocorticotropic hormone (ACTH) due to a pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), menstrual disorders, and weight gain. Treatment includes radiation, chemotherapy, and the use of certain hormone-inhibiting drugs.
The pituitary ACTH hypersecretion pipeline products market research report provides comprehensive information on the therapeutics under development for pituitary ACTH hypersecretion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for pituitary ACTH hypersecretion and features dormant and discontinued projects.
Pituitary ACTH Hypersecretion Pipeline Products Market Segmentation by Targets
The key targets in the pituitary ACTH hypersecretion pipeline products market are Adrenocorticotropic Hormone Receptor, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 7, Cyclin Dependent Kinase 9, Cytochrome P450 11B2 Mitochondrial, Heat Shock Protein 90, Pro Opiomelanocortin, Somatostatin Receptor Type 2, Somatostatin Receptor Type 4, and Somatostatin Receptor Type 5. All of them have the same number of products in the pipeline.
Pituitary ACTH Hypersecretion Pipeline Products Market Analysis by Targets
For more target insights into the pituitary ACTH hypersecretion pipeline products market, download a free report sample
Pituitary ACTH Hypersecretion Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the pituitary ACTH hypersecretion pipeline products market are Adrenocorticotropic Hormone Receptor Antagonist, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 7 Inhibitor, Cyclin Dependent Kinase 9 Inhibitor, Cytochrome P450 11B2 Mitochondrial Inhibitor, Heat Shock Protein 90 Inhibitor, Pro Opiomelanocortin Inhibitor, Somatostatin Receptor Type 2 Agonist, Somatostatin Receptor Type 4 Agonist, and Somatostatin Receptor Type 5 Agonist. All of them have the same number of products in the pipeline in 2022.
Pituitary ACTH Hypersecretion Pipeline Products Market Analysis by Mechanisms of Action
For more MoA insights into the pituitary ACTH hypersecretion pipeline products market, download a free report sample
Pituitary ACTH Hypersecretion Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the pituitary ACTH hypersecretion pipeline products market are oral and subcutaneous. Oral is the leading RoA in the pituitary ACTH hypersecretion pipeline drugs market.
Pituitary ACTH Hypersecretion Pipeline Products Market Analysis by Routes of Administration
For more RoA insights into the pituitary ACTH hypersecretion pipeline products market, download a free report sample
Pituitary ACTH Hypersecretion Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the pituitary ACTH hypersecretion pipeline products market are small molecule, antisense RNAi oligonucleotide, and synthetic peptide. The small molecule accounted for the highest number of pituitary ACTH hypersecretion drugs in development in terms of molecule type in 2022.
Pituitary ACTH Hypersecretion Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the pituitary ACTH hypersecretion pipeline products market, download a free report sample
Pituitary ACTH Hypersecretion Pipeline Products Market - Competitive Landscape
Some of the leading companies in the pituitary ACTH hypersecretion pipeline products market are Crinetics Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, Diurnal Group Plc, Recordati SpA, and Strongbridge Biopharma plc. All companies have equal number of products in the Cushing disease pipeline products market.
Pituitary ACTH Hypersecretion Pipeline Products Market Analysis by Companies
To know more about the leading pituitary ACTH hypersecretion pipeline products market players, download a free report sample
Pituitary ACTH Hypersecretion Pipeline Products Market Report Overview
Key Targets | Adrenocorticotropic Hormone Receptor, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 7, Cyclin Dependent Kinase 9, Cytochrome P450 11B2 Mitochondrial, Heat Shock Protein 90, Pro Opiomelanocortin, Somatostatin Receptor Type 2, Somatostatin Receptor Type 4, and Somatostatin Receptor Type 5 |
Key MoA | Adrenocorticotropic Hormone Receptor Antagonist, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 7 Inhibitor, Cyclin Dependent Kinase 9 Inhibitor, Cytochrome P450 11B2 Mitochondrial Inhibitor, Heat Shock Protein 90 Inhibitor, Pro Opiomelanocortin Inhibitor, Somatostatin Receptor Type 2 Agonist, Somatostatin Receptor Type 4 Agonist, and Somatostatin Receptor Type 5 Agonist |
Key RoA | Oral and Subcutaneous |
Key Molecule Type | Small Molecule, Antisense RNAi Oligonucleotide, and Synthetic Peptide |
Leading Companies | Crinetics Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, Diurnal Group Plc, Recordati SpA, and Strongbridge Biopharma plc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for pituitary ACTH hypersecretion.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the pituitary ACTH hypersecretion pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Cyclacel Pharmaceuticals Inc
Diurnal Group Plc
Recordati SpA
Strongbridge Biopharma plc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the pituitary ACTH hypersecretion pipeline products market?
The key targets in the pituitary ACTH hypersecretion pipeline products market are Adrenocorticotropic Hormone Receptor, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 7, Cyclin Dependent Kinase 9, Cytochrome P450 11B2 Mitochondrial, Heat Shock Protein 90, Pro Opiomelanocortin, Somatostatin Receptor Type 2, Somatostatin Receptor Type 4, and Somatostatin Receptor Type 5.
-
What are the key mechanisms of action in the pituitary ACTH hypersecretion pipeline products market?
The key MoA in the pituitary ACTH hypersecretion pipeline products market are Adrenocorticotropic Hormone Receptor Antagonist, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 7 Inhibitor, Cyclin Dependent Kinase 9 Inhibitor, Cytochrome P450 11B2 Mitochondrial Inhibitor, Heat Shock Protein 90 Inhibitor, Pro Opiomelanocortin Inhibitor, Somatostatin Receptor Type 2 Agonist, Somatostatin Receptor Type 4 Agonist, and Somatostatin Receptor Type 5 Agonist.
-
What are the key routes of administration in the pituitary ACTH hypersecretion pipeline products market?
The key RoA in the pituitary ACTH hypersecretion pipeline products market are oral and subcutaneous.
-
What are the key molecule types in the pituitary ACTH hypersecretion pipeline products market?
The key molecule types in the pituitary ACTH hypersecretion pipeline products market are small molecule, antisense RNAi oligonucleotide, and synthetic peptide.
-
Which are the leading companies in the pituitary ACTH hypersecretion pipeline products market?
Some of the leading companies in the pituitary ACTH hypersecretion pipeline products market are Crinetics Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, Diurnal Group Plc, Recordati SpA, and Strongbridge Biopharma plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.